Tsuzuki Motohiro, Inaguma Youko, Handa Kousuke, Hasegawa Akio, Yamamoto Yukiya, Watanabe Masato, Mizuta Syuichi, Maruyama Fumio, Okamoto Masataka, Emi Nobuhiko
Department of Internal Medicine, Fujita Health University, School of Medicine, Toyoake.
Intern Med. 2009;48(16):1433-5. doi: 10.2169/internalmedicine.48.2084. Epub 2009 Aug 17.
Contraception is recommended during imatinib therapy based on the teratogenicity data in rats. However, patients may become pregnant and here we describe a successful pregnancy and labor without any congenital anomaly in a patient with chronic myeloid leukemia (CML) under treatment with imatinib. The patient had received imatinib for 53 months before she became pregnant, with a complete cytogenetic response achieved after 6 months of therapy and a major molecular response (MMR) after 28 months. CML was in MMR at discovery of pregnancy and the fetus had been exposed to imatinib for 5 weeks. Treatment was discontinued, but MMR persisted during gestation.
基于大鼠致畸性数据，伊马替尼治疗期间建议采取避孕措施。然而，患者仍有可能怀孕，在此我们描述了1例接受伊马替尼治疗的慢性髓性白血病（CML）患者成功妊娠并分娩，且未出现任何先天性异常的情况。该患者在怀孕前已接受伊马替尼治疗53个月，治疗6个月后获得完全细胞遗传学缓解，28个月后获得主要分子学缓解（MMR）。妊娠时CML处于MMR状态，胎儿暴露于伊马替尼5周。治疗中断，但妊娠期间MMR持续存在。
